Mafalda Oliveira, MD, PhD, on Clinical Implications of New Findings on Camizestrant in Advanced Breast Cancer

Posted: Thursday, January 5, 2023

Mafalda Oliveira, MD, PhD, of Spain’s Vall d’Hebron University Hospital and Institute of Oncology, discusses the apparent advantages of camizestrant, an oral selective estrogen receptor degrader, which improved progression-free survival in patients with hormone receptor–positive, HER2-negative breast cancer when compared with fulvestrant. Follow-up studies are already underway, combining camizestrant with a CDK4/6 inhibitor.